The estimated Net Worth of Dawn Carter Bir is at least $34 Million dollars as of 15 August 2023. Ms. Bir owns over 1,205 units of Reata Pharmaceuticals Inc stock worth over $5,826,630 and over the last 8 years she sold RETA stock worth over $26,148,651. In addition, she makes $1,975,900 as Executive Vice President and Chief Commercial Officer at Reata Pharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Ms. Bir RETA stock SEC Form 4 insiders trading
Dawn has made over 7 trades of the Reata Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 1,205 units of RETA stock worth $203,404 on 15 August 2023.
The largest trade she's ever made was selling 96,996 units of Reata Pharmaceuticals Inc stock on 6 March 2023 worth over $8,503,639. On average, Dawn trades about 8,115 units every 39 days since 2016. As of 15 August 2023 she still owns at least 33,805 units of Reata Pharmaceuticals Inc stock.
You can see the complete history of Ms. Bir stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dawn Bir biography
Dawn C. Bir serves as Executive Vice President, Chief Commercial Officer of the Company. Prior to joining Reata, Ms. Bir most recently served as Vice President of Sales with Pharmacyclics, LLC. From February 2013 to September 2016, she built and led their first hematology national sales organization of sales representatives, division managers and regional sales directors, responsible for the launch of IMBRUVICA® in the US and Puerto Rico. From October 2011 to February 2013, Ms. Bir served as Vice President Sales & Marketing with McKesson US Pharmaceutical, SKY Pharmaceuticals and RxPak. Prior thereto, she held positions of increasing responsibility within McKesson Corporation, Genentech, Inc. and Bristol-Myers Squibb Company. She currently serves on the board of directors of Geron Corporation, a publicly-traded company. Ms. Bir holds a B.S. in Biology from Binghamton University.
What is the salary of Dawn Bir?
As the Executive Vice President and Chief Commercial Officer of Reata Pharmaceuticals Inc, the total compensation of Dawn Bir at Reata Pharmaceuticals Inc is $1,975,900. There are 4 executives at Reata Pharmaceuticals Inc getting paid more, with Manmeet Soni having the highest compensation of $12,612,200.
How old is Dawn Bir?
Dawn Bir is 49, she's been the Executive Vice President and Chief Commercial Officer of Reata Pharmaceuticals Inc since 2018. There are 9 older and 6 younger executives at Reata Pharmaceuticals Inc. The oldest executive at Reata Pharmaceuticals Inc is Michael D. Wortley, 73, who is the Exec. VP & Chief Legal Officer.
What's Dawn Bir's mailing address?
Dawn's mailing address filed with the SEC is 2801 Gateway Dr #150, Irving, TX 75063, USA.
Insiders trading at Reata Pharmaceuticals Inc
Over the last 8 years, insiders at Reata Pharmaceuticals Inc have traded over $176,850,875 worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth $179,313,590 . The most active insiders traders include Holdings A/S Novo, R Kent Jr Mc Gaughy, and Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of $10,950,893. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth $546,195.
What does Reata Pharmaceuticals Inc do?
reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
What does Reata Pharmaceuticals Inc's logo look like?
Complete history of Ms. Bir stock trades at Geron, Reata Pharmaceuticals Inc, and Soleno Therapeutics Inc
Reata Pharmaceuticals Inc executives and stock owners
Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Manmeet Soni,
Chief Financial Officer, Chief Operating Officer, Executive Vice President -
J. Warren Huff,
Chairman of the Board, President, Chief Executive Officer -
Colin Meyer,
Executive Vice President, Chief Research and Development Officer -
Michael Wortley,
Executive Vice President, Chief Legal Officer -
Dawn Bir,
Executive Vice President, Chief Commercial Officer -
Manmeet Singh Soni,
COO, CFO & Pres -
J. Warren Huff,
Chairman & CEO -
Dr. Colin J. Meyer M.D.,
Exec. VP & Chief Innovation Officer -
Michael D. Wortley,
Exec. VP & Chief Legal Officer -
Dawn Carter Bir,
Exec. VP & Chief Commercial Officer -
Jack Nielsen,
Independent Director -
William McClellan,
Independent Director -
William Rose,
Independent Director -
R. Kent McGaughy,
Independent Director -
Vineet Jindal,
Vice President, Corporate Communications and Strategy -
Martin Edwards,
Independent Director -
Seemi Khan,
Chief Medical Officer -
Andrea Loewen,
Vice President - Global Regulatory Affairs -
Kevin Johnston,
Chief Technical Officer, Vice President -
Steve Harman,
VP & Chief HR Officer -
Dakota Gallivan,
VP & Chief Healthcare Compliance Officer -
Dr. W. Christian Wigley Ph.D.,
Sr. VP & Chief Scientific Officer -
Bhaskar Anand,
VP & Chief Accounting Officer -
William Puffin Partners, L....,
-
Dennis K. Stone,
Director -
Elaine Castellanos,
VP, Chief Accounting Officer -
Holdings A/S Novo,
10% owner -
James Edward Bass,
Director -
James W Jr Traweek,
-
Inc Cpmg,
-
Inc. Abb Vie,
10% owner -
Keith Wayne Ward,
See Remarks -
William Rose Evelyn P.Edwar...,
-
William Puffin Partners, L....,
-
Antal Rohit Cpmg Inc Desai,
-
William Montrose Investment...,
-
William Charles Henry Rose ...,
-
William Puffin Partners, L....,
-
William Estate Of Edward W....,
-
Jason Douglas Wilson,
Executive VP of Operations -
Pharma Llcstapleton Craig R...,
-
Christy J. Oliger,
Director -
Shamim Ruff,
Director -
Bhaskar Anand,
SVP, Chief Accounting Officer -
Steven Ryder,
Director -
Samina Khan,
SVP, Chief Medical Officer -
Rajiv Patni,
EVP, Chief R&D Officer